{"id":60447,"date":"2024-12-06T10:02:35","date_gmt":"2024-12-06T09:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/"},"modified":"2024-12-06T10:02:35","modified_gmt":"2024-12-06T09:02:35","slug":"alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/","title":{"rendered":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery"},"content":{"rendered":"
\n

\nMultiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput<\/b><\/p>\n

LAUSANNE, Switzerland–(BUSINESS WIRE)–Alithea Genomics<\/a>, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS\u2122 Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow and full transcript coverage in a unique RNA-seq workflow. The technology is compatible with both 96- and 384-well plate formats and up-to 384 full-length RNA-seq library preps can be performed in a single tube without RNA isolation.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cFull-Length DRUG-seq enables us to detect a wide range of biologically meaningful gene features and a much higher number of different transcripts, isoforms and splicing variants as compared to our 3\u2019 mRNA-seq solutions,\u201d said Riccardo Dainese, PhD, CEO and co-founder of Alithea Genomics. \u201cFor the first time, scientists are able to perform large-scale compound screening based on full-length RNA sequencing, which could open up new avenues in the discovery of new drugs that have a specific effect on gene isoforms and splicing.\u201d<\/p>\n

\nThe MERCURIUS\u2122 Full-Length DRUG-seq technology allows the preparation of Illumina-compatible RNA sequencing libraries for up to 384 samples in a time and cost-efficient manner. The kit enables full-length transcript coverage, as opposed to 3′ coverage of the standard DRUG-seq kit, detecting over 40,000 different transcripts at only 4M reads\/sample, reaching similar levels to non-multiplexed gold standard techniques. Furthermore, the technology allows the detection of different isoforms, splicing variants, and alternative promoters.<\/p>\n

\n\u201cThe availability of Full-Length DRUG-seq is the latest in a series of new technology launches that we will continue through 2025. These new products and services will continue to leverage sample multiplexing and extraction-free procedures on an increasing number of sample types, and with shorter and faster processing times,\u201d Dr. Dainese added.<\/p>\n

\nAlithea is now accepting orders for MERCURIUS\u2122 Full-Length DRUG-seq kits<\/a> and services<\/a>.<\/p>\n

\nAbout RNA Sequencing
\n
<\/b>RNA sequencing examines the quantity and sequences of RNA in a biological sample using next-generation sequencing (NGS). This data specifies which of the genes encoded in DNA are turned on or off, and to what extent, e.g., in a diseased cell or in response to a drug or different environmental conditions. This improved understanding of cellular biology can help guide decisions in multiple key steps of the drug discovery and development process.<\/p>\n

\nAlithea commercializes massively multiplexed library preparation solutions for RNA sequencing. These technologies enable the preparation of hundreds of RNA samples for sequencing in a single tube. Traditional preparation of samples for RNA sequencing is expensive and time consuming, due to the large amounts of reagents and manual operations that are typically required. Alithea\u2019s BRB-seq (Bulk RNA Barcoding and Sequencing) technology drastically decreases the cost, time and resource consumption associated with RNA sequencing preparation.<\/p>\n

\nAbout Alithea Genomics
\n
<\/b>Alithea Genomics<\/a> is committed to developing solutions that simplify and streamline the generation of “big RNA data”, which we believe will constitute the foundation of tomorrow’s research and medicine. Our BRB-seq technologies and kits enable researchers to discover novel biomarkers and essential data needed to develop new drugs at a fraction of the traditional cost and time. Alithea Genomics was founded in May 2020 at the EPFL in Lausanne, Switzerland.<\/p>\n

Contacts<\/b> <\/p>\n

\nAlithea Genomics
\n
Riccardo Dainese
\n
media@alitheagenomics.com<\/a><\/p>\n

\nHalsin Partners
\n
Mike Sinclair
\n
msinclair@halsin.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Multiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput LAUSANNE, Switzerland–(BUSINESS WIRE)–Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS\u2122 Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60447","6":"format-standard","7":"category-industry"},"yoast_head":"\nAlithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Multiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput LAUSANNE, Switzerland–(BUSINESS WIRE)–Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS\u2122 Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T09:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery\",\"datePublished\":\"2024-12-06T09:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/\"},\"wordCount\":558,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241206255474\\\/en\\\/2324258\\\/22\\\/Alithea_Logo_2024.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/\",\"name\":\"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241206255474\\\/en\\\/2324258\\\/22\\\/Alithea_Logo_2024.jpg\",\"datePublished\":\"2024-12-06T09:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241206255474\\\/en\\\/2324258\\\/22\\\/Alithea_Logo_2024.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241206255474\\\/en\\\/2324258\\\/22\\\/Alithea_Logo_2024.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend","og_description":"Multiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput LAUSANNE, Switzerland–(BUSINESS WIRE)–Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS\u2122 Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/","og_site_name":"Pharma Trend","article_published_time":"2024-12-06T09:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery","datePublished":"2024-12-06T09:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/"},"wordCount":558,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/","url":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/","name":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg","datePublished":"2024-12-06T09:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241206255474\/en\/2324258\/22\/Alithea_Logo_2024.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/alithea-genomics-launches-full-length-drug-seq-to-unlock-full-power-of-transcriptomics-for-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60447"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60447\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}